Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Eversource Energy

ES

NEUTRAL

May 27, 2026

Research Conclusion

ES is a HOLD at $67.17 — the business is excellent (natural monopoly, 95%+ regulated revenue, 8.3% rate base CAGR to $49.3B by FY2030) but the current price delivers ~6.7%/yr total return, marginally below the 7.25% cost of equity. The investment case is a regulated income compounder plus regulatory normalization option: Aquarion Water sale ($2.4B, H2 2026) resolves the credit overhang; FERC headwind clears FY2027+; CT PURA improvement is possible but uncertain. ACCUMULATE below $62; BUY below $58 where near-zero perpetual dividend growth is priced in and starting yield reaches 5.4%. Trim above $80. Max 4% position cap.

Company Overview & Moat Assessment

Eversource Energy is the largest regulated utility in New England, operating electric and gas distribution across Connecticut, Massachusetts, and New Hampshire, plus (pending sale) Aquarion Water. Revenue ~$13.5B (FY2025). Business is 95%+ regulated, providing natural monopoly status with zero competitive risk. Current LT debt of $27.2B (declining to ~$24.8B post-Aquarion close). FY2026 guided non-GAAP EPS of $4.57–$4.72, dividend $3.15/share (4.69% yield). $26.5B five-year CapEx plan (FY2026–2030) drives rate base from $30.6B to $49.3B.

▲ Bull Case

  • CT PURA grants 9.0%+ allowed ROE in the next rate case; Aquarion closes H2 2026 stabilizing credit to BBB; FY2027 EPS reaches $5.30+; market re-rates to 16x driving ~$85 price (+36.4% total return).
  • $26.5B CapEx plan at 8.3% rate base CAGR is approved, permitted, and funded — delivering 5–7% EPS CAGR from FY2027 onward independent of any regulatory improvement, with the FERC headwind resolved after FY2027 leaving pure rate base accretion.
  • Aquarion proceeds reduce LT debt ~$2.4B (saving ~$84M/yr interest), resolve Fitch BBB Watch Negative to BBB Stable, simplify earnings mix to pure electric + gas regulated operations, and catalyze 10–15% multiple expansion from currently depressed levels.

▼ Bear Case

  • CT PURA awards below 8.5% allowed ROE, signaling structurally impaired regulatory relationship rather than cyclical adversity — permanently impairing earnings power in ES's largest segment and removing the regulatory normalization thesis leg.
  • Aquarion sale fails or is delayed beyond Q2 2027, leaving $27.2B debt unreduced, Fitch Watch Negative unresolved, $84M/yr interest savings unrealized, and the balance sheet repair thesis broken; FY2027 EPS stuck at $4.60–4.70 with no visible growth path at 11–12x = ~$52 (−13.2% total return).
  • BBB− credit downgrade triggers forced selling by investment-grade mandates, raises blended funding cost 50–100bps on $27.2B debt ($140–280M/yr incremental interest), constrains CapEx funding, and puts dividend sustainability at risk — particularly severe if combined with new offshore wind contingent liability disclosure >$200M.
Primary Debate on Wall Street

Analyst median price target ~$70–75 (mixed Hold/Buy); consensus broadly agrees with the base-case framework. Most expect the Aquarion close (H2 2026) to be the near-term positive re-rating catalyst and the CT rate case outcome to be the medium-term thesis driver in either direction. Few are outright bullish given regulatory complexity — CT PURA's history of hostility since 2020 (storm penalties, below-average allowed ROEs) keeps sentiment cautious. The debate centers on: (1) whether CT PURA's adversity is cyclical (normalizable) or structural (permanent); (2) the true composition and resolution timeline of $645M in offshore wind contingent liabilities; and (3) whether Aquarion proceeds will be consumed by contingent liabilities before they reduce debt.

Top Catalysts
  • Aquarion Water sale close (H2 2026) — $2.4B proceeds reduce debt, resolve Fitch Watch Negative to BBB Stable, save ~$84M/yr interest; expect significant re-rating within 60–90 days of close
  • CT PURA rate case outcome (2026 filing expected) — allowed ROE at or above 9.0% confirms regulatory normalization thesis; partial improvement (8.7–9.2%) supports base case
  • FERC ROE refund completion (FY2027) — removes ~$70M/yr headwind; FY2027 EPS normalization to $5.00–5.20 is near-certain and mathematically visible
  • FY2026 Q2/Q3 earnings guidance updates (July/October 2026) — any upward revision or confirmation of $4.65 midpoint validates earnings floor thesis
  • Sector-wide utility re-rating from interest rate decline — 50bps rate drop adds ~$4–6 to intrinsic value at current yield levels
Top Risks
  • CT PURA awards below 8.5% allowed ROE — signals structural rather than cyclical impairment; triggers Kill Switch #1 (reduce 30%)
  • Fitch or S&P credit downgrade to BBB−/Baa3 — forced selling by IG mandates, $140–280M/yr incremental interest on $27.2B debt, dividend sustainability risk; triggers Kill Switch #2 (reduce 25%)
  • Aquarion sale fails or delayed past Q2 2027 — eliminates balance sheet repair thesis, leaves credit overhang unresolved; triggers Kill Switch #3 (reduce 20%)
  • New offshore wind contingent liability disclosure exceeding $200M — ~$645M in remaining potential obligations post-exit; consumes Aquarion proceeds before debt reduction; triggers Kill Switch #5 (reduce 15%)
  • FY2026 non-GAAP EPS guidance revised below $4.30 for two consecutive periods — breaks earnings floor thesis; at $67.17 = 15.6x trough P/E with no normalization path; triggers Kill Switch #4 (reduce 20%)

Full Memo Continues

5 more sections, locked

  • Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/ES/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.